Figure 1: Group photo following the signing ceremony of the collaboration agreement between Adara Bio and TFBS Bioscience. From left to right: Mr. Robert Fergusson, Representative of Australian in Taiwan; Mr. Jitto Arulampalam, Chairman of Adara Bio; Dr. Ta-Tung Yuan, Chairman and Chief Executive Officer of TFBS Bioscience; and Dr. Michael Huang, Director of Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO).
During the visit, the Adara Bio and Centre for Eye Research Australia (CERA) teams also participated in a series of exchange activities in Taiwan. These included visits to leading research and clinical institutions, such as National Taiwan University Hospital and Academia Sinica, as well as a meeting with Dr. Chien-Jen Chen, President of Academia Sinica.
Established in Australia earlier this year (2026), Adara Bio is a joint venture between Medic Vision AI Limited, Medigen’s Australian subsidiary, and the Centre for Eye Research Australia (CERA). The company focuses on applying its innovative RNA Base Editing Platform to develop innovative gene therapies for inherited retinal diseases (IRDs).
Building on the foundation of collaboration between Taiwan and Australia, we look forward to accelerating the commercialization of Adara Bio’s gene therapy technologies and bringing hope to patients suffering from vision loss.
Figure 2. Group photo of the teams from Medigen Biotechnology Corp., Medic Vision AI Limited, Adara Bio, CERA, and TFBS Bioscience following the signing ceremony.
Related Media Coverage
1. Economic Daily News — July 15, 2026
New Opportunities for Taiwan–Australia Biomedical Collaboration: Academia Sinica and the Centre for Eye Research Australia Hold Bilateral Discussions
https://money.udn.com/money/story/10871/9629516?from=edn_related_storybottom&shem=isphe
2. Commercial Times — July 16, 2026
TFBS Bioscience Partners with Australia’s Adara Bio to Pursue AAV Gene Therapy Manufacturing Opportunities
https://www.ctee.com.tw/news/20260716701889-430504